Table 1 Inadequacy rate of PGFNAB and USGFNAB in each study
Researcher & Year | Number of nodules | PGFNAB | USGFNAB | Source |
|---|---|---|---|---|
Takashima 1994 [9] | 330 | 4% (10/268) | 19% (12/62) | 23 |
Danese 1998 [10] | 9683 | 9% (433/4986) | 3.5% (167/4697) | 15 |
Hatada 1998 [11] | 166 | 30% (28/94) | 17% (12/72) | 17 |
Carmeci 1998 [12] | 497 | 16% (60/370) | 7% (9/127) | 18 |
Goudy 2005 [13] | 89 | 11.5% (9/78) | 0% (0/11) | 16 |
Cesur 2006 [14] | 285 | 32% (92/285) | 21.5% (61/285) | 13 |
Izquierdo 2006 [15] | 376 | 11% (19/170) | 7% (16/225) | 14 |
Can 2008 [16] | 386 | 27% (55/202) | 13% (23/184) | 19 |
Krishnappa 2013 [17] | 91 | 11% (6/91) | 2% (2/91) | 20 |
Guo 2015 [18] | 489 | 2% (2/101) | 2% (8/388) | 12 |
Sharma 2017 [19] | 410 | 15% (36/237) | 0.5% (1/173) | 21 |
Choong 2018 [7] | 2322 | 4.5% (50/1123) | 5% (55/1199) | 7 |
Taha 2020 [5] | 962 | 17% (98/570) | 13% (51/392) | 5 |